Welcome to our dedicated page for Petvivo Holdings news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on Petvivo Holdings stock.
PetVivo Holdings, Inc. (PETVW) reports developments tied to its veterinary biomedical device business and its PetVivo Animal Health and PetVivo AI subsidiaries. The company focuses on manufacturing, commercializing and licensing medical devices and therapeutics for companion animals, equines and equine athletes, including Spryng with OsteoCushion Technology and PrecisePRP.
Recurring news includes financial results, regulatory acknowledgements, investor presentations, product commercialization, licensing activity and updates on PetVivo.ai, an artificial intelligence platform for veterinary practice engagement. Company announcements also describe its strategy of adapting human therapies for animal-health applications and expanding commercial availability through veterinary and distribution channels.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PetVivo Holdings, a biomedical device company focused on innovative therapeutics for pets, will present at the Aegis Capital Virtual Conference from May 2nd to 4th, 2023. CEO John Lai will discuss the company's Spryng product featuring OsteoCushion Technology, aimed at managing lameness and joint issues in companion animals.
Spryng is an injectable device that supports joint health by mimicking natural cartilage and is currently available for sale. The presentation is scheduled for May 3rd, 2023, from 12:25 PM to 12:55 PM ET. PetVivo holds a strong patent portfolio, with 17 products in development and a unique market strategy focused on veterinary devices.
PetVivo Holdings (NASDAQ: PETV, PETVW) has appointed Mary Grace Rutland as the new Business Development Manager for the Mid-Atlantic Region. Rutland, with 24 years of experience in animal health sales, will focus on promoting Spryng with OsteoCushion technology to veterinarians across the U.S. CEO John Lai expressed excitement about her addition, highlighting her previous roles in the industry, including positions at Fort Dodge Animal Health and Neogen Corporation. PetVivo specializes in innovative medical devices for companion animals, with Spryng aimed at treating lameness and joint-related conditions like osteoarthritis in dogs and horses. The company has a pipeline of 17 products and holds 19 patents covering its biomaterials and methods.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announces its participation at the ACVSMR Symposium from April 28-29, 2023, in Charleston, South Carolina. The company will showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed for managing joint afflictions in pets, particularly osteoarthritis. This event provides a platform for PetVivo to demonstrate its innovative veterinary medical device to experts in the field. CEO John Lai emphasized the importance of this opportunity to discuss how Spryng can enhance the quality of life for companion animals. The company’s focus is on leveraging human therapies for veterinary applications, with a pipeline containing seventeen products and a portfolio of nineteen patents.
PetVivo Holdings (NASDAQ: PETV, PETVW) has appointed Spencer Breithaupt to its Board of Directors, bringing over 30 years of experience in the animal health industry. Breithaupt, previously with MWI Animal Health and Fortune 500 companies, is expected to enhance the company's industry relationships and strategic direction. CEO John Lai expressed confidence that Breithaupt's expertise will be instrumental in advancing PetVivo’s mission. The company specializes in biomedical devices for companion animals and currently offers its lead product, SPRYNG with OsteoCushion technology, which is designed to manage joint-related afflictions in animals.